ATE495193T1 - Bag3-antikörper zur nutzung in forschung, diagnose und der behandlung von krankheiten, an denen zelltod beteiligt ist - Google Patents

Bag3-antikörper zur nutzung in forschung, diagnose und der behandlung von krankheiten, an denen zelltod beteiligt ist

Info

Publication number
ATE495193T1
ATE495193T1 AT02799075T AT02799075T ATE495193T1 AT E495193 T1 ATE495193 T1 AT E495193T1 AT 02799075 T AT02799075 T AT 02799075T AT 02799075 T AT02799075 T AT 02799075T AT E495193 T1 ATE495193 T1 AT E495193T1
Authority
AT
Austria
Prior art keywords
diagnostics
research
treatment
cell death
diseases involving
Prior art date
Application number
AT02799075T
Other languages
English (en)
Inventor
Arturo Leone
Maria Caterina Turco
Original Assignee
Biouniversa Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biouniversa Srl filed Critical Biouniversa Srl
Application granted granted Critical
Publication of ATE495193T1 publication Critical patent/ATE495193T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT02799075T 2001-12-28 2002-12-30 Bag3-antikörper zur nutzung in forschung, diagnose und der behandlung von krankheiten, an denen zelltod beteiligt ist ATE495193T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01830834A EP1323733A1 (de) 2001-12-28 2001-12-28 BAG3-Nukleotid- und Proteinsequenzen zur Nutzung in Forschung, Diagnose und der Behandlung von Krankheiten, an denen Zelltod beteiligt ist
PCT/EP2002/014802 WO2003055908A2 (en) 2001-12-28 2002-12-30 Bag3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases

Publications (1)

Publication Number Publication Date
ATE495193T1 true ATE495193T1 (de) 2011-01-15

Family

ID=8184857

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02799075T ATE495193T1 (de) 2001-12-28 2002-12-30 Bag3-antikörper zur nutzung in forschung, diagnose und der behandlung von krankheiten, an denen zelltod beteiligt ist

Country Status (11)

Country Link
US (2) US7537760B2 (de)
EP (2) EP1323733A1 (de)
AT (1) ATE495193T1 (de)
AU (1) AU2002364302A1 (de)
CA (1) CA2471924C (de)
CY (1) CY1111371T1 (de)
DE (1) DE60238945D1 (de)
DK (1) DK1465927T3 (de)
ES (1) ES2359396T3 (de)
SI (1) SI1465927T1 (de)
WO (1) WO2003055908A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1397083B1 (it) * 2009-12-04 2012-12-28 Biouniversa Srl Marcatore biochimico serico
KR101436684B1 (ko) 2012-03-09 2014-09-01 가톨릭대학교 산학협력단 저산소성 허혈 예방 또는 치료용 조성물
ITMI20130403A1 (it) * 2013-03-18 2014-09-19 Biouniversa Srl Anticorpi anti-bag3 per uso terapeutico
EP2676966A1 (de) * 2012-06-19 2013-12-25 Biouniversa S.r.l. BAG3 als biochemisches Serum und Gewebemarker
ITMI20131351A1 (it) * 2013-08-07 2015-02-08 Biouniversa Srl Molecole leganti il recettore di bag3 per uso terapeutico.
HUE052814T2 (hu) * 2014-01-31 2021-05-28 Temple Univ Of The Commonwealth System A szívelégtelenség terápiájához célfehérjeként alkamazott BAG3
ITUB20155097A1 (it) 2015-11-05 2017-05-05 Biouniversa Srl Anticorpi umanizzati anti-BAG3
IT201600069391A1 (it) * 2016-07-04 2016-10-04 Univ Degli Studi Di Salerno Uso della proteina bag3 e suoi frammenti peptidici per il controllo dell’omeostasi vascolare
IT201600111877A1 (it) 2016-11-07 2018-05-07 Biouniversa Srl Anti-BAG3 antibodies in combination with inhibitors of immune check-point for therapeutic use
WO2019020734A1 (en) 2017-07-28 2019-01-31 Biouniversa S.R.L. ANTI-BAG3 ANTIBODIES AS THERAPEUTIC REAGENTS IN CARDIOVASCULAR DISEASES
WO2021140173A1 (en) 2020-01-10 2021-07-15 Biouniversa S.R.L. Methods and uses for treating fibrotic solid tumors with bags inhibitors
IL312509A (en) * 2021-10-22 2024-07-01 Univ Loyola Chicago BAG3 methods and uses for treating inflammation
JP2025514489A (ja) * 2022-05-03 2025-05-02 テンプル ユニバーシティー オブ ザ コモンウェルス システム オブ ハイアー エデュケーション 脳におけるｂａｇ３およびタンパク質品質管理

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652223A (en) * 1994-03-14 1997-07-29 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services DNA encoding CAI resistance proteins and uses thereof
JPH10327872A (ja) * 1997-05-30 1998-12-15 Otsuka Pharmaceut Co Ltd Ｂｃｌ−２相互作用蛋白遺伝子ｂｉｓ
US6696558B2 (en) * 1998-09-09 2004-02-24 The Burnham Institute Bag proteins and nucleic acid molecules encoding them
JP2002524068A (ja) * 1998-09-09 2002-08-06 ザ バーナム インスティチュート 新規なｂａｇタンパク質およびそれらをコードする核酸分子

Also Published As

Publication number Publication date
US20090306192A1 (en) 2009-12-10
CA2471924C (en) 2013-11-12
SI1465927T1 (sl) 2011-05-31
WO2003055908A2 (en) 2003-07-10
CY1111371T1 (el) 2015-08-05
DK1465927T3 (da) 2011-04-18
ES2359396T3 (es) 2011-05-23
AU2002364302A8 (en) 2003-07-15
AU2002364302A1 (en) 2003-07-15
US7537760B2 (en) 2009-05-26
CA2471924A1 (en) 2003-07-10
EP1323733A1 (de) 2003-07-02
WO2003055908A3 (en) 2004-03-11
DE60238945D1 (de) 2011-02-24
EP1465927A2 (de) 2004-10-13
US20050176660A1 (en) 2005-08-11
EP1465927B1 (de) 2011-01-12

Similar Documents

Publication Publication Date Title
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
ATE495193T1 (de) Bag3-antikörper zur nutzung in forschung, diagnose und der behandlung von krankheiten, an denen zelltod beteiligt ist
ATE432291T1 (de) Kdr-peptide und diese enthaltende impfstoffe
ATE433996T1 (de) Humane dr4-antikörper und deren anwendungen
DE602005019064D1 (de) Verfahren zur herstellung gefriergetrockneter blutplättchen, gefriergetrocknete blutplättchen enthaltende zusammensetzungen und verwendungsverfahren
DK1450799T5 (da) Arulurinstofforbindelser sammen med andre cytostatiske eller cytotoksiske midler til behandling af humane cancere
ATE411805T1 (de) Organo-phosphorverbindungen zur aktivierung von gamma/delta-t-zellen
DK1212422T3 (da) Humane CTLA-4-antistoffer og anvendelserne deraf
DE69316948D1 (de) Lösliche Liganden für CD40
ATE350385T1 (de) Neue aryl fructose-1,6-bisphosphatase inhibitoren
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
DE69927688D1 (de) Antivirales Mittel in Kombination mit Strahlentherapie zur Verwendung in der Behandlung von Krebs
ATE534649T1 (de) Imidazothiazole und imidazoxazolderivative als inhibitoren von p38
ATE128128T1 (de) Antiatherosclerotische und antithrombotische 2- amino-6-phenyl-4h-pyran-4-one.
MXPA05011085A (es) Composiciones y metodos relacionados a stop-1.
EA200500934A1 (ru) Соединения, модулирующие активность киназного белка множественных линий, и способы лечения нейродегенеративных и воспалительных заболеваний
ATE311476T1 (de) Polymorphismen im gen für den humanen organischen anionentransporter c (oatp-c)
ATE328000T1 (de) Phospholipidester von clofarabin
ATE435284T1 (de) Zusammensetzungen und verfahren zur therapie und diagnose von lungenkrebs
DE10342518A1 (de) Plasminogen-Aktivatoren mit verringerter Lysin-Bindungskapazität
ATE414776T1 (de) Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen
DE60224778D1 (de) Zusammensetzungen und Verfahren zur Behandlung und zur Detektion von proliferativen Störungen die mit der Überexpression des menschlichen "Transketolase like-1" gens in Zusammenhang stehen
DE60219495D1 (de) Verwendung von Interleukin-18 zur Behandlung von UV-assoziierten Hautkrankheiten
DE602004006566D1 (de) Verfahren zur Diagnose und Behandlung von Metastasen und dafür nützliche Zusammensetzung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1465927

Country of ref document: EP